Integrated care pathways for airway diseases (AIRWAYS-ICPs)

To cite this version:

HAL Id: hal-02565409
https://hal.umontpellier.fr/hal-02565409
Submitted on 6 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Integrated care pathways for airway diseases (AIRWAYS-ICPs)

European Innovation Partnership on Active and Healthy Ageing, Action Plan B3 Mechanisms of the Development of Allergy (MeDALL, WP10) GARD (Global Alliance against Chronic Respiratory Diseases, WHO) research demonstration project

The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).
Affiliations: University Hospital Montpellier, Montpellier, France. MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Region Languedoc Roussillon, France. MeDALL, Mechanisms of the Development of Allergy. ARIA, Allergic Rhinitis and its Impact on Asthma. European Academy of Allergy and Clinical Immunology. EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site. EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action. UM1, University 1, Montpellier, France. Fondation Partenariale, France. EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Region Emilia-Romagna, Italy. National Heart and Lung Institute, Imperial College London and Royal Brompton and Harefield NIHR Biomedical Research Unit, London, UK. Romanian Alliance Against Chronic Respiratory Diseases. Faculty of Medicine, Transilvania University, Brasov, Romania. Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBER Enfermedades Respiratorias, Barcelona, Spain. Hospital Clinic/FCRB, Barcelona, Spain. Centre for Research in Environmental Epidemiology (CREAL), IMIM (Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra (UPF), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. Dept Respiratory Medicine, Ghent University Hospital, Gent, Belgium. ENT Dept, Ghent University Hospital, Gent, Belgium. Research Centre in Respiratory Medicine (CIMER), Faculty of Medicine, Catholic University, Cordoba, Argentina. Shanghai Respiratory Research Institute, Chinese Medical Association, Shanghai, China. Chinese Alliance against Lung Cancer. European Respiratory Society, Astana City, Kazakhstan. PDNR, Portuguese National Programme for Respiratory Diseases. Division of Pulmonology, Dept of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa. Health Innovation Centre of Southern Denmark, Region of Southern Denmark, Denmark. Academic Medical Centre, University of Amsterdam, The Netherlands. Bangladesh Lung Foundation and National Institute of Diseases of Chest and Hospital, Dhaka, Bangladesh. Centre for Individualised Medicine, Dept of Clinical and Experimental Sciences, Linköping University, Linköping, Sweden. EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Agra Anducia, Spain. Andalusian Healthcare Service, Spain. Deputy National Medical Director, NHS England, UK. Dept of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, Odense, Denmark. ERS, European Respiratory Society, University of Milan. J Public Health and Infectious Diseases "Sapienza" University of Rome, Rome, Italy. Second University of Naples and Institute of Translational Medicine, Italian National Research Council, Naples, Italy. Institut universitaire de cardiology et de pneumologie de Quebec, Université Laval, Quebec City, QC, Canada. INSERM, U1046, Montpellier, France. National Institute for Health Research, Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, UK. Health Economics and Tufe of Health Care and Wellbeing, University of Glasgow, Glasgow, UK. Depts of Clinical Epidemiology, and Biostatistics and Medicine, McMaster University, Hamilton, ON, Canada. Pulmonary Dept, III, Medical Centre, Mainz University Hospital, Mainz, Germany. Dept of Paediatric Respiratory Medicine, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UK. University of Costa Rica, San Jose, Costa Rica. Section of Allergy and Clinical Immunology, Imperial College London, Royal Brompton Hospital, London, UK. Institute of Ageing and Chronic Disease, University of Liverpool and University Hospital Aintree, Liverpool, UK. Dept of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil. Allergy and Respiratory Diseases, IRCCS San Martino - IST- University of Genoa, Dept of Internal Medicine, Genoa, Italy. NAIH, National Allergy Health Programme, Norway. University of Oslo and Oslo University Hospital, Dept of Paediatrics, Oslo, Norway. University of Rome "Tor Vergata" Dept of System Medicine, Rome, Italy. Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia. ESE, Sociedad Latinoamericana de Asma, Asma e Inmunologia. IRCCS, San Raffaele Pisana, Rome, Italy. National Cooperative Group of Paediatric Research on Asthma, Asthma Clinic and Education Center of the Beijing Peking University Hospital, Beijing, PR China. Chachava Clinic, David Tvdiliani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia. IPCRG, International Primary Care Respiratory Group. Dept of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. GARD, Global Alliance against Chronic Respiratory Diseases (WHO). Pulmonology Research Institute and Russian Respiratory Society, Moscow, Russia. Faculty of Medicine, The Catholic University of León, Spain. European Innovation Partnership on Active and Healthy Ageing, Reference Site, NHS Scotland, Glasgow, UK. Centre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK. ProAR, Nucleo de Excelencia em Asma, Federal University of Bahia and CNPq, Salvador, Brazil. University of Manchester, Manchester, UK. DIA, The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. SFDA, Societe francaise d'allergologie. Strasbourg University, Strasbourg, France. EUREGHA, European Regions and Health Authorities, Brussels, Belgium. University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. UPRES, EA 220, Université Versailles Saint Quentin, Hôpital Foch, Suresnes, France. SPLF, Société de Pneumologie de Langue Francaise. Dept of Respiratory Medicine, University of Toulouse, Toulouse, France. Service de Physiologie, Paris Descartes University EA 2511, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France. University Southampton Faculty of Medicine and NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK. University Clinic of Pulmology and Allergy, University "Ss. Cyril and Methodius", Skopje, Macedonia. Service de pneumo-allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Algiers, Algeria. LSACI, Lithuanian Society of All., Lithuanian Society of Allergy and Clinical Immunology. Vilnius University Hospital, Lithuania. NHS R&D North West, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK. EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, NHS Scotland, Edinburgh, UK. Dept of Oncology, Haematology and Respiratory Diseases, Policlinic of Modena, University of Modena and Reggio Emilia, Modena, Italy. GAAPPI, Global Allergy and Asthma Patient Platform, Vienna, Austria. Education for Health, Warwick, UK. European Rhinology Society. Porto Age-Up Consortium, Porto, Portugal. Dept of Health Information and Decision Sciences and CINTEST, Porto University Medical School, Allergy, Hospital S. Joao and Instituto and Hospital CUF Porto, Porto, Portugal. Internal and Geriatric Medicine, University of Nice - Sophia Antipolis, Nice, France. Repatriation General Hospital, Adelaide, Australia. Director of Public Health, Wakefield Council, Wakefield, UK. 7th Respiratory Medicine Dept and
Asthma Centre, Athens Chest Hospital, Athens, Greece. 15EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Valencia, Spain. 16Polibienestar Research Institute, University of Valencia, Valencia, Spain. 17National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia. 18Immunology and Allergology Division, Dept of Medicine, Clinical Hospital University of Chile, Santiago, Chile. 19Dept of Allergy, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland. 20Director of Public Health for Blackburn with Darwen, Blackburn, UK. 21Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK. 22Dept of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Belgium. 23Director of Public Health for Kirklees, Huddersfield, UK. 24School of Psychology, University of Plymouth, Plymouth, UK. 25EIP on AHA Reference Site, Region-Campania, Italy. 26Dept of Medicine and Surgery, University of Salerno, Salerno, Italy. 27IRCCS Multimedica, Milan, Italy. 28Respiratory Diseases, Escola Paulista de Medicina of Federal University of Sao Paulo, Sao Paulo, Brazil. 29The George Institute for Global Health and The University of Sydney, Sydney, Australia. 30Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, UK. 31Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea. 32GARD-Turkey, Global Alliance against Chronic Respiratory Diseases (GARD), Turkey. 33Hacettepe University School of Medicine, Paediatric Allergy and Asthma Unit, Hacettepe, Ankara, Turkey. 34Director of Public Health, Lancashire, UK. 35Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany. 36Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany. 37CARO, Czech Alliance against Chronic Respiratory Diseases. 38Dept Immunology, Rheumatology and Allergy, Faculty of Medicine, University Medical Centre, Lodz, Poland. 39Karolinska Institutet, Dept of Clinical Science and Education, Institute of Environmental Medicine, Stockholm, Sweden. 40Polastoma, Poland. 41Dept of Internal Medicine, Asthma and Allergy, Barticzi Hospital Medical University, Medical University of Lodz, Lodz, Poland. 42Pulmonology and Allergology Center, Vilnius University, Vilnius, Lithuania. 43University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam. 44CHU Liege, GIGA Research Center, University of Liege, Liege, Belgium. 45Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK. 46Directorate of Finance, eHealth and Pharmaceuticals, Scottish Government Health Directorates, Edinburgh, Bratislava, Slovakia. 47Dept of Medicine, Royal College of Surgeons in Ireland (Medical School) Bon Secours Hospital, Dublin, Ireland. 48Kronikgune, Basque Region, Spain. 49Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (INRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran. 50Royal Brompton Hospital, London, UK. 51Geneva Medical School and University Hospitals, Geneva, Switzerland. 52University Hospital of Zagreb, Croatia. 53Institute of Pneumology Marius Nasta, Bucharest, Romania. 54Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 55Serbian Alliance against Chronic Respiratory Diseases. 56Association for Asthma and COPD in Serbia. 57Bordeaux University, Bordeaux, France. 58Paris Descartes University, Dept of Public Health and Biostatistics, EA 4064 and Paris Descartes and SPLF, Société. 59SPARC, Societé Portuagale de Alergologia e Imunologia Clinica, Portugal. 60Respiratory National Clinical Director, NHS England, UK. 61Service de Médecine Interne et Pathologies Professionnelles, Hôpital Polyclinique de Dakar (IHS), Dakar, Sénégal. 62Mustapha Hospital, Algiers, Algeria. 63Hospital of the Hospitalier Brothers in Buda, Budapest, Hungary. 64GALEN, Global Allergy and Asthma European Network. 65Charité University Hospital, Allergy Centre Charité, Berlin, Germany. 66Service de Pneumologie, 1011 CHUV-Lausanne, Lausanne, Switzerland. 67Dept of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Australia. 68National Hospital Organization, Tokyo National Hospital and Teikyo University School of Medicine, Tokyo, Japan. 69Cardio-Thoracic and Vascular Dept, University Hospital of Pisa, Pisa, Italy. 70EFA, European Federation of Allergy and Airways Diseases patients' associations, Poznan, Poland and Dissemination (CRDI), University of York, UK. 71Allergy Dept, 2nd Paediatric Clinic, University of Athens, Athens, Greece. 72Ferrara University, Ferrara, Italy. 73NMD Research Building, University of Oxford, Oxford, UK. 74SPLF, Espace francophone de Pneumologie. 75Children’s Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia. 76University of Groningen, Dept of Pneumology, GRIAC Research Institute University Medical Center Groningen, Netherlands. 77Academic Primary Care, University of Aberdeen, Aberdeen, UK. 78Christian Albrechts University Kiel, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DLZ), Germany. 79Research Institute INCLIVA, University of Valencia, CIBERObn, Health Institute Carlos III, Madrid, Spain. 80University of Nebraska Medical Center, Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska Medical Center, Omaha, NE, USA. 81Respiratory Nurse Consultant, Salford Royal NHS Foundation Trust, Salford, UK. 82INSERM, U710 and 988, Montpellier, France. 83Pneumologie, AP-HP, Hôpital Cochin - Site Val de Grâce, Université Paris Descartes and SPLF, Société de Pneumologie de Langue Française, Paris, France. 84Arcispedale, S.Maria Nuova Hospital, Reggio Emilia, Italy. 85Association Asthme et Allergies, Boulogne-Billancourt, France. 86Woodbrook Medical Centre, Loughborough, UK. 87Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Medical School, Edinburgh, UK. 88Dept of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland. 89Dept of Allergy and Clinical Immunology, Centro Medico-Doncente La Trinidad, Caracas, Venezuela. 90Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA. 91Child Health, Queen’s University Belfast, Belfast, UK. 92Dept of Thoracic Medicine, Institute of Clinical Research, University of Heraklion, Heraklion, Greece. 93University Hospital of Mont-Godinne, Catholic University of Louvain, Yvoir, Belgium. 94Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1138 “Neurophysiologie Respiratoire Expérimentale et Clinique”, Paris, France. 95INSERM, UMR_S 1158 “Neurophysiologie Respiratoire Expérimentale et Clinique”, Paris, France. 96AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Charles Foix, Service de Pneumologie et Réanimation Médicale (Département “R3”), Paris, France. 97Fonds de Dotation Recherche en Santé Respiratoire - Fondation du Souffle, Paris, France. 98National Advisory Group, Respiratory Managed Clinical Networks in Scotland. 99HITT, Health Institute for Technology Transfer, Barcelona, Spain. 100EuroAsian Respiratory Society, Bishkek, Kyrgyzstan. 101National Centre Cardiology and Internal Medicine, Bishkek, Kyrgyzstan. 102Pulmonary Division, InCor (Heart Institute), Hospital da Clinicas da
Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil. 159Dept of Neonatal Intensive Care, Oslo University Hospital, Ullevaal, Faculty of Medicine, University of Oslo, Oslo, Norway. 160European Academy of Paediatrics (EAP-UEMS). 161Regional Medical Manager (North), NHS England, UK. 162Observatoire wallon de la santé, Direction générale opérationnelle Pouvoirs locaux, action sociale et Santé, Service public de Wallonie, Belgium. 163Immunology Department, Coimbra University Hospital, Coimbra, Portugal. 164Dept of Pathophysiology and Allergy Research, Centre of Pathophysiology, Infectology and Immunology, Medical University of Vienna, Vienna, Austria. 165LACRD, Lithuanian National Alliance Against Chronic Respiratory Diseases. 166Dept of Lung Diseases and Clinical Allergology, University of Turku, Finland. 167Pharmacoeconomics and Unit and Respiratory Medicine, CHU-Lyon and UMR CNRS 5558, Claude-Bernard University Lyon, Lyon, France. 168FILHA, Finnish Lung Association. 169Respiratory and Allergy Research Group, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. 170Dept of Respiratory Medicine J, Odense University Hospital, Odense, Denmark. 171EIP on AHA B3 Action Group (Delivering Integrated Care Models), Regional Agency for Health and Social Care, Arcispedale S.Maria Nuova/IRCCS, Research Hospital, Reggio Emilia, Italy. 172CNR, Institutes of Biomedicine and Molecular Immunology (IBIM), Palermo, and of Clinical Physiology (IFC), Pisa, Italy. 173German Center for Lung Research (DZL), Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. 174Sotiria Hospital, Athens, Greece. 175Acting Director of Public Health, Cumbria County Council, Carlisle, UK. 176Hôpital Albert Calmette, CHRU, Lille, France. 177Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. 178North of England EU Health Partnership, UK. 179Olmsted Medical Center, Dept of Research and University of Minnesota, Dept of Family and Community Health, Rochester, MN, USA. 180Cyprus International Institute for Environmental and Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus. 181The Allergy and Asthma Institute, Pakistan. 182Dept of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa. 183Guangzhou Institute of Respiratory Diseases and State Key Laboratory of Respiratory Diseases, Guangzhou Medical College, Guangzhou, China. 184University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.

Correspondence: A. Bedbrook, MACVIA-ARIA, Hopital Arnaud de Villeneuve, Service Maladies Respiratoires, 34295 Montpellier, France. E-mail: anna.bedbrook@insERM.fr

Introduction

Chronic respiratory diseases: from guidelines to policies

Chronic respiratory diseases are major non-communicable diseases [1]. Asthma and allergic diseases occur throughout the life cycle and can begin during pregnancy and childhood. In Europe, they affect 30 million children and adults under 45 years of age. Chronic obstructive pulmonary disease (COPD) has an estimated annual death rate of over 4 million people globally. Among the European Union (EU) member states, asthma accounted for an average of 53 hospital admissions per 100,000 population in 2009, and the average COPD-related admission rate was 184 [2]. The annual direct and indirect costs in the 28 EU countries due to COPD or asthma are estimated at €48 billion and €34 billion, respectively [2]. Chronic respiratory diseases affect active and healthy ageing. Asthma in children or adults is a common risk factor for COPD in adults [3, 4].

Guidelines for COPD [5] and rhinitis–asthma comorbidity [6] exist using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach [7, 8]. Global strategies have also been proposed for the prevention and control of asthma [9] and COPD [10]. However, in older adults, it is often difficult to differentiate between asthma and COPD [11], and none of the current guidelines appear to have a specific module for older people [12].

Effective strategies are needed to reduce chronic respiratory disease burden. National programmes (e.g. the Finnish, Czech or Portuguese asthma or COPD programmes [13, 14]) can be cost-effective [15], but they are insufficiently implemented in the EU. Integrated care pathways (ICPs) for COPD (QS10) exist in the UK (National Institute for Health and Care Excellence, NICE) [16], in France (Haute Autorité de Santé) and in the Netherlands [17-19], but ICPs for asthma or asthma and rhinitis comorbidity do not exist. Asthma quality standards for asthma (QS25) have been published by NICE [20]. These are specific, concise statements that act as markers of high-quality, cost-effective patient care. Moreover, some initiatives are aimed at also incentivising good practice and improving implementation (i.e. remuneration based on performance indicators). In the UK, the Quality and Outcomes Framework has four asthma-specific performance indicators which are explicitly linked to the subsequent remuneration of providers [21].

Support statement: The study was funded by Région Languedoc-Roussillon.
In low-resource settings, some successful attempts to combine all non-communicable diseases into one single action plan have been developed [22–24] for the implementation of the World Health Organization (WHO) non-communicable disease action plan. However, such combined plans are not available for the management of non-communicable diseases in high-resource settings.

The Polish Presidency of the EU Council (3051st Council Conclusions) has made the prevention, early diagnosis and treatment of asthma and allergic diseases a priority to reduce health inequalities [25, 26]. The 3206th Cyprus Council Conclusions recommended that the diagnosis and treatment of chronic diseases should be initiated as early as possible to improve active and healthy ageing [27]. A debate at the European Parliament (Cyprus Presidency of the EU Council, 2012) recommended early diagnosis and management of chronic respiratory diseases in children in order to promote active and healthy ageing [28].

**Protective and risk factors**

Chronic respiratory diseases and other non-communicable diseases often share environmental risk factors (e.g. tobacco, nutrition, indoor and outdoor air pollution, and sedentary lifestyle) [1, 29], leading to sustained local and systemic inflammation [30, 31] and impaired ageing. Tobacco smoking is the best-identified risk factor for many non-communicable diseases, including chronic respiratory disease.

The prevention and control of chronic diseases could be considered sequentially before the disease has been identified in order to 1) prevent its onset (health promotion and primary prevention), and 2) better control and prevent the short- and long-term consequences after its onset (secondary and tertiary prevention and control).

Starting in early childhood, the foundations for healthy or weakened respiratory organs are laid from a political perspective to feed into the goals of the Europe 2020 strategy as well as healthy and active ageing [32]. Multi-sectoral prevention, including policy change, regulation and market intervention, is of the highest priority.

**Integrated care pathways**

ICPs, also known as clinical pathways or care pathways, are structured multidisciplinary care plans which detail essential steps in the care of patients with a specific clinical problem [33]. They promote the translation of guidelines into local protocols and their subsequent application to clinical practice. An ICP forms all or part of the clinical record, documents the care given, and facilitates the evaluation of outcomes for continuous quality improvement [34]. ICPs empower patients as well as their health and social carers.

ICPs differ from practice guidelines as they are utilised by a multidisciplinary team, and focus on the quality and co-ordination of care. ICPs need to record variations from planned care [35]. An ICP is intended to inform and encourage thought and adaptation. Clinicians are free to exert their own professional judgments as appropriate. However, any alteration to the practice identified within the ICP must be noted as a variance [36]. Variance analysis may be used to optimise the ICPs linked with pay-for-performance [37–40], audit and feedback, and integration of recommendations with electronic medical records.

ICPs are already the standard of care in different areas of medicine, such as oncology [41] or palliative care [42]. Some have already been proposed for asthma or COPD.

The care pathways simulator, a discrete event simulation software programme, helps to view the system from the perspective of the task, job or patient, rather than of the function [43]. Service redesign, targeted at improving services, can bring benefit to patients, carers, staff and National Health Service (NHS) trusts [44].

**European Innovation Partnership on Active and Healthy Ageing**

European innovation partnerships attempt to enhance EU competitiveness and to tackle societal challenges by fostering innovation. They address the weaknesses in EU research and innovation that complicate the discovery or exploitation of knowledge and may hinder innovation into the market place.

Active and healthy ageing is a major societal challenge common to all countries and to all populations [45]. Ageing is intertwined with socioeconomic inequalities [46], is an under-appreciated cause of poverty and hinders economic development, particularly affecting underserved populations and females. Active and healthy ageing needs to be promoted very early in life to be successful.

The European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) is deployed in three areas and six action plans [47]:

- [37x782]INTEGRATED CARE PATHWAYS FOR AIRWAY DISEASES | J. BOUSQUET ET AL. DOI: 10.1183/09031936.00014614
• Prevention of diseases and health promotion
  • Innovative ways to ensure that patients adhere to their treatments (A1)
  • Innovative solutions for personalised health management, with focus on falls prevention (A2)
  • Action for preventing functional decline and frailty, with a particular focus on malnutrition (A3)
  • Care and cure: scaling up and replication of successful innovative integrated care models for chronic diseases among older patients, such as through remote monitoring (B3)
  • Active and independent living of older adults by improving the uptake of interoperable independent living solutions including guidelines for business models (C2)
  • Horizontal topics: networking and knowledge sharing on innovation for age-friendly environments (D4)

The EIP on AHA aims to provide a framework for supporting bottom-up innovations and a forum for professional collaboration. The partners work on a voluntary basis to pool their knowledge and expertise in order to deploy, scale-up and replicate innovative health and care services.

The implementation of the strategy and action plan of WHO Europe on healthy ageing [48] has synergies with a number of the priorities and actions identified in the strategic implementation plan of the EIP on AHA, and shares its positive vision of ageing.

Objectives of AIRWAYS-ICPs
The general objective of AIRWAYS-ICPs is to develop multi-sectoral ICPs for CRDs used across European countries and regions in order to 1) reduce the burden of the diseases, 2) promote active and healthy ageing, and 3) create a care pathways simulator tool which can be applied in older adults. AIRWAYS-ICPs will not duplicate existing EU prevention programmes in chronic respiratory diseases (e.g. anti-smoking) but will strengthen them where appropriate.

The aim of AIRWAYS-ICPs is to propose central unifying themes and an overall potential to gain political leverage in the current environment and to better understand and manage the spectrum of care for patients with chronic airway disease in European countries and regions. It will also aim to generalise the approach to the uniform definition of severity, control and risk of severe asthma presented to the WHO [49], as well as of allergic diseases [50], in order to develop a uniform risk stratification usable for chronic respiratory diseases in most situations.

AIRWAYS-ICPs will propose a feasible, achievable and manageable project from science to guidelines (fig. 1) using existing networks and partners committed to Action Plan B3 of the EIP on AHA.

Specific objectives include the following:
1) To collect guidelines and ICPs that exist in European countries and regions for airway diseases (asthma, COPD and rhinitis).
2) To strengthen prevention and health promotion for airway diseases.
3) To stratify patients with severe chronic respiratory diseases.
4) To understand AIRWAY diseases in children and adolescents and to develop ICPs (P.A.R.I.S).

![Figure 1: From science to guidelines and best practices.](https://example.com/)
5) To develop important questions on chronic respiratory diseases for older people.

6) To understand and overcome barriers in chronic respiratory disease management.

7) To develop ICPs for rhinitis and asthma comorbidity across the life cycle, and for COPD and asthma in older people, combining preventive and disease control strategies based on existing national (or regional) programmes (e.g. Finnish or Portuguese asthma, COPD and allergy programmes).

8) To develop a simulation tool of ICPs for rhinitis and asthma comorbidity that could be applied to older people and to redesigning care pathways.

9) To tackle chronic respiratory diseases across the life cycle, placing a particular interest in the cultural and social aspects of the diseases in a project centred on the patient.

10) To implement multi-sectoral, multi-country initiatives to allow the practical use of AIRWAYS-ICPs by European countries and regions, and beyond to other countries, for cost-effective policies on the prevention and control of asthma, COPD and allergy.

AIRWAYS-ICPs working group

The AIRWAYS-ICPs working group has included the WHO Global Alliance against Chronic Respiratory Diseases and WHO Collaborating Center (2001–2013) working groups (64 countries). Moreover, we have attempted to include as many European countries as possible (23 EU countries) and it should be noted that Serbia, Croatia, Slovenia and Slovakia, who were not included in the previous study groups, are now included with a large number of representatives. Moreover, we have enhanced the study group by including social carers and public health researchers. Patients are well represented. In some countries, the names of the representatives have been proposed by governmental organisations. Finally, through the EIP on AHA, European Regions and Health Authorities (EUREGHA), other representatives were included, in particular NHS England, Scotland and Northern Ireland, as well as Wallonie and Southern Denmark. The working group now includes all the stakeholders required for the development of multi-sectoral ICPs.

AIRWAYS-ICPs

1) To collate existing ICPs, national programmes and guidelines

Tools used in the 28 EU countries and other European countries will be collected with regards to ICPs for COPD, asthma and rhinitis. This approach will be deployed to other countries. A repository is being developed by the EIP on AHA to collect projects such as:

1) Good practices of the B3 Action Group on integrated care.

2) The Finnish plans for asthma [13], allergy [51] and COPD [14] which are considered to be the prototypes of national plans for chronic respiratory diseases. Polastma (Poland) is, in particular, derived from the asthma plan.

3) The Portuguese National Programme for Respiratory Diseases (PNDR), the first national programme to include all respiratory diseases.

4) Care pathways provided by national institutions (e.g. NICE in the UK or the Haute Autorité de Santé in France).

5) The WHO guidelines for asthma and COPD in low-income settings.

6) A common approach to severe asthma and allergic diseases.

7) International Primary Care Respiratory Group mapping of national guidelines used by primary care for COPD, asthma, rhinitis, community-acquired pneumonia, obstructive sleep apnoea and smoking cessation [52].

2) To strengthen EU policies for the prevention of chronic respiratory diseases

The European Commission addresses chronic respiratory disease as a key priority and includes legislation on tobacco consumption and ambient air quality, work on climate change, and actions under the European Environment and Health Strategy. These policies tie in with active Commission support for the current United Nations process to address non-communicable diseases and related socioeconomic and environmental determinants. There is an urgent need to strengthen prevention and health promotion, in particular for smoking cessation (“Health for Growth” public health programme), improved physical and social environment, and promotion of lifestyle of beneficial value for “whole of society” and “vulnerable groups” in particular [53].
3) Stratification of patients with severe chronic respiratory diseases

Severity is the intrinsic severity of the disease process, control is the degree to which therapy goals are met, and responsiveness is the ease with which control is achieved by therapy. The concept of severity and control has been largely developed for asthma in guidelines [54]. The uniform definition of severe asthma [55] presented to the WHO [49] used an approach derived from the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines [56]. This approach has also been used for all allergic diseases (fig. 2) [50] and may be used for COPD (table 1).

The stratification of patients with chronic respiratory diseases can be generalised using the approach of the uniform definition of severe asthma presented to the WHO [55], in order to have a uniform definition of severity, control and risk usable in most situations. This uniform definition will make it possible to better define the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes and the development of novel therapies targeted to better defined phenotypes.

4) Understanding airway diseases in children and adolescents and developing ICPs (P.A.R.IS)

Allergic diseases and asthma often start early in life, and most patients will have developed disease before the age of 18 years. It is therefore important to understand the risk factors and mechanisms underlying allergic chronic respiratory diseases and asthma in childhood, as well as to determine the gaps in the management of these diseases in preschool children, school children and adolescents. The prevention of early diagnosis and the management of chronic respiratory diseases in children is vital for the improvement of active and healthy ageing.

Within the framework of the EIP on AHA, the European Academy of Allergy and Clinical Immunology (EAACI) has decided, in collaboration with Allergic Rhinitis and its Impact on Asthma (ARIA), to develop a programme to better understand AIRWAY diseases in children and to propose a framework for the development of ICPs in this age group, considering rhinitis and asthma as a single entity.

The Allergy Sentinel Network, approved by the European Parliament, will be developed in Paris [28].

5) Development of important questions on chronic respiratory diseases for older people

Clinically important questions on the diagnosis and management of chronic respiratory diseases in older adults will be defined using a three-step Delphi process. The questions include COPD, asthma, rhinitis and chronic respiratory disease comorbidities. Multi-sectoral experts and patients are included.
First Delphi round: experts were asked to propose the three major problems they would like to have answered concerning disease in older people, including comorbidities.

Second Delphi round: the questions were assessed by a group of four experts (two methodologists) to check for redundancy among the questions proposed (similar wording).

Third Delphi round: the questions were sent to the group for agreement.

Fourth Delphi round: the harmonised questions will be sent to 60 experts who will rank them.

The prioritised questions include: 1) asthma in older people; 2) COPD in older people; 3) rhinitis in older people; 4) comorbidities of asthma and COPD in older people; and 5) how paediatric interventions have an impact on ageing associated with respiratory diseases.

The list of questions will also be customised in order to be applicable to all countries and targeted to low, middle and high-income settings within which socioeconomic and health problems differ. The third Delphi round will be reviewed by two expert panels: one from developing countries and another from developed countries.

The prioritised questions will be answered after a review of available evidence using the GRADE approach.

Further to the first completed steps, it was felt that a better definition was needed for airway diseases and how they cluster in comorbidities (respiratory and non-respiratory). There are likely to be differences within the life cycle.

### TABLE 1 Stratification steps for severe asthma and chronic obstructive pulmonary disease (COPD)

<table>
<thead>
<tr>
<th></th>
<th>Asthma</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Underdiagnosis</strong></td>
<td>Common</td>
<td>Extremely common</td>
</tr>
<tr>
<td></td>
<td>If asthma is not diagnosed, severe exacerbations can occur</td>
<td>Patients usually consult when they have (very) severe disease or an exacerbation</td>
</tr>
<tr>
<td></td>
<td>Asthma deaths mostly occur in untreated patients</td>
<td>If diagnosed earlier, smoking cessation measures could be initiated and prevent the worsening of COPD and comorbidities</td>
</tr>
<tr>
<td></td>
<td>In occupational asthma, early diagnosis is needed</td>
<td></td>
</tr>
<tr>
<td><strong>Effective treatment</strong></td>
<td>Preventive treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smoking cessation effective (at least when started early)</td>
<td>Somewhat effective on symptoms</td>
</tr>
<tr>
<td></td>
<td>High variability due to different COPD phenotypes (e.g. chronic bronchitis and emphysema)</td>
<td>Modestly effective on exacerbations, possibly because phenotypes are not well characterised and COPD encompasses several different phenotypes which may respond differently to drugs</td>
</tr>
<tr>
<td></td>
<td>No treatment effective on decline of lung function</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Drugs</strong></td>
<td>Inhaled corticosteroids and β2-agonists very effective on symptoms and control</td>
<td>Smoking cessation effective (at least when started early)</td>
</tr>
<tr>
<td></td>
<td>At regular doses, no treatment is clearly effective on remodelling</td>
<td>Somewhat effective on symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High variability due to different COPD phenotypes (e.g. chronic bronchitis and emphysema)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Modestly effective on exacerbations, possibly because phenotypes are not well characterised and COPD encompasses several different phenotypes which may respond differently to drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No treatment effective on decline of lung function</td>
</tr>
<tr>
<td><strong>Treatment availability and affordability</strong></td>
<td></td>
<td>A global problem</td>
</tr>
<tr>
<td><strong>Differential diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Many “uncontrolled” patients with current asthma medications have asthma and another disease or another disease (e.g. bronchiectasis)</td>
<td>Many COPD patients have a differential diagnosis (including lung cancer)</td>
</tr>
<tr>
<td><strong>Compliance and literacy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For smoking cessation</td>
</tr>
<tr>
<td><strong>Inhaler misuse</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Smoking and other risk factors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mood, depression and socioeconomic status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Controlled disease with high intensity treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A large number of patients fall into this category If treatment is stopped, exacerbations can occur quickly</td>
<td>Phenotypes are not well characterised and COPD encompasses several different diseases (e.g. chronic bronchitis and emphysema) that may respond differently to drugs Phenotypic characterisation is urgently needed</td>
</tr>
</tbody>
</table>
6) Understanding and overcoming barriers in chronic respiratory disease management
Many barriers exist and prevent the deployment and use of a non-communicable disease global approach in different settings and countries.

7) Development of ICPs for rhinitis and asthma comorbidity across the life cycle, and for COPD, asthma and comorbidities in older people
1) To develop multi-sectoral ICPs which can be used across Europe and in other countries.
2) For asthma and rhinitis comorbidity, the P.A.R.I.S approach (EAACI–ARIA) will be used in children and the ARIA approach in adults and older people.
3) A combined approach to asthma and COPD has been proposed for older people, as the two diseases overlap and are often difficult to differentiate, particularly at the primary care level. Moreover, non-respiratory comorbidities will be included since older patients often have several diseases with poly-pharmacy.
4) To combine strategies for prevention and control.
5) To place a special emphasis on older and/or underserved patients.
6) To implement cost-effective policies for the prevention of chronic respiratory diseases.
7) To promote active and healthy ageing. AIRWAYS-ICPs places a particular interest in cultural and societal aspects of the diseases in a project centred on the patient.
8) Interactions will take place between several sections of AIRWAYS-ICPs in order to develop ICPs (fig. 3). Health technology assessment will lead to recommendations that will be evaluated in each country (or EU region) in order to develop multi-sectoral ICPs which may differ depending on the differences within the health systems, and on the socioeconomic and political priorities of the different countries.

FIGURE 3 Development of integrated care pathways (ICPs).
8) **Redesign care pathways using simulator tools (in older people)**

Health costs associated with the long-term care of older people have increased in all countries. Computer-based simulation tools may provide integrated care services to older people. The simulation is used for decision-making in healthcare systems by increasing efficiency and reducing unnecessary cost, while maintaining or improving quality of care [57]. It is linked to the processes of change or reform of the system [58], and is used as a tool to address the complexity of healthcare systems (healthcare ecosystem) in which all stakeholders interact (patients, managers, policy makers and professionals). Examples are applied to infectious diseases [59]. The simulation allows the identification of treatment effects in longitudinal healthcare data [60], preventing technology-induced errors in healthcare [61]. In the area of “AIRWAYS ICPs”, computational analysis has been used to analyse the role of asthma in airway mechanics parameters [62].

LTTCMAS (Long-Term Care Multi-Agent Systems) [63] is a simulator that, as a starting point, used a holistic model of care systems for people that need long-term care, the Sustainable Socio-Health Model (SSHM). The implementation of the simulator on the Jason multi-agent platform allows the tool to include human interactions, preferences and social abilities that take place between older people and the staff of healthcare systems (health and social workers). The use of this multi-agent platform provides the required scalability for simulating population sizes of different orders of magnitude. The closed-loop design of the proposed simulator permits repeated simulation of successive interactions of the target population with the healthcare system. The simulator may forecast the long-term effects of different policies on the considered population as well as on the healthcare system.

Using the Spanish simulation tool LTCMAS [63] as a prototype, a new version will be adapted to the AIRWAYS patient group (LCT+ AIRWAYS ICPs). LCT+ AIRWAYS ICPs will be available in primary care centres through health information systems to assist physicians in the stratification of patients and choice of pathways, including an attempt to include resource use/cost implications.

9) **Tackling chronic respiratory diseases across the life cycle**

Pre-natal and early-life events have a major impact on the development of chronic diseases in adults [64, 65] and older people, including diabetes [66], coronary heart diseases [67], asthma [68], COPD [3] or neurodegenerative diseases [69]. A better understanding of these links will make it possible to propose effective novel prevention strategies to promote active and healthy ageing.

The developmental origin of ageing is on the EU political agenda. The Polish Priority of the EU Council (2011) promoted the recognition, prevention and management of chronic respiratory diseases in children to ultimately affect healthy ageing [26]. The developmental determinants of non-communicable diseases in ageing were reinforced during the Cyprus Presidency of the EU Council (2012), which proposed to fight against non-communicable diseases across the life cycle [27]. A meeting at the European Parliament, organised by the Region Languedoc Roussillon and under the auspices of the Cyprus EU Priority (November 2012), was focussed on chronic respiratory diseases [28].

In order to find novel health promotion strategies in non-communicable diseases and to promote value creation, pre-natal and early life events were discussed in a meeting on December 2–3, 2013 by the Region Languedoc Roussillon and under the auspices of the frame of Action B3 of the EIP on AHA.

10) **Multi-sectoral, multi-country initiative**

Members of each European country will be involved in a multi-sectoral approach: primary and secondary care, healthcare professionals (including pharmacists and nurses), social carers, patients and policy makers. Patients’ organisations and major European scientific societies are partners of the WHO Collaborating Centre for Asthma and Rhinitis for this initiative. EUREGHA will help to deploy AIRWAYS-ICPs in the EU regions. Partners outside the EU will also be involved in the initiative. Education and coaching for all stakeholders with patients’ organisations will be developed.

Interactions with the private sector have already been established with, as an example, Eurobiomed (www.eurobiomed.org; Commitment for Action B3 Action Plan), the focal point for the economic growth of MACVIA-LR (Contre les Maladies Chroniques pour un Vieillissement Actif; Fighting Chronic Diseases for Active and Healthy Ageing).

**Added value**

AIRWAYS-ICPs is a demonstration project that follows the recommendations of the EU (Council Conclusions) [25, 26] and which may be the model for ICPs in other chronic diseases for Action Plan B3 of the EIP on AHA.
ACKNOWLEDGEMENTS

The members of the AIRWAYS-ICPs study group are as follows: J. Bousquet (University Hospital Montpellier; MACVIA-IR, Fighting Chronic Diseases for Healthy Ageing, Region Languedoc Roussillon; MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; UM1, University 1, Montpellier; and Fondation Partenariale, France), A. Addis (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action, Region Emilia-Romagna, Italy), I. Adcock (National Heart and Lung Institute, Imperial College London and Royal Brompton and Harefield NIHR Biomedical Research Unit, London, UK), I. Agache (ARIA, Allergic Rhinitis and Its Impact on Asthma; Romanian Alliance against Chronic Respiratory Diseases; Faculty of Medicine, Transylvania University, Brasov, Romania), A. Agusti (Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBER Enfermedades Respiratorias, Spain), N. Aıı (Faculty of Medicine, Transylvania University, Brasov, Romania), A. Alonso (Hospital Clinic/FGB, Barcelona, Spain), P. Altan (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), C.A. Aktis (SIAF, Swiss Institute of Allergy and Asthma Research and University of Zurich; and Christine Kühne · Center for Allergy Research and Education, Davos, Switzerland), M. Akdis (SIAF, Swiss Institute of Allergy and Asthma Research and University of Zurich, Switzerland), A. Alonso (Hospital Clinic/FGB, Barcelona, Spain), P. Altan (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), T. Altunsu (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), C. Andersen (APFQ, Associação Portuguesa de Fibrose Quística), A. Andrianarisoa (SPLF, Espace francophone de Pneumologie), I. Annesi-Maesano (ARIA, Allergic Rhinitis and Its Impact on Asthma), I.J. Ansotegui (ARIA, Allergic Rhinitis and Its Impact on Asthma), J.M. Anto (MeDALL, Mechanisms of the Development of Allergy; Centre for Research in Environmental Epidemiology (CREAL); IMIM (Hospital del Mar Medical Research Institute); Universitat Pompeu Fabra (UPF); and CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain), L. Araújo (Porto Age-Up consortium; APA, Associação Portuguesa de Asmáticos, Portugal), T. de Araùjo (FPP, Fundação Portugueza do Pulmão), A. Arias Cruz (Colegio Mexicano de Inmunología Clínica y Allergia; Slaai, Sociedad Latinoamericana de Allergia, Asma e Imunologia), N. Arpacı (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), A. Arrobas (PNDR,


